title: [In vitro activity of telithromycin against community acquired respiratory pathogens].
abstract: BACKGROUND
  Telithromycin is a new ketolide antimicrobial, that can be useful for the treatment of respiratory infections.
  
  
  OBJECTIVE
  To compare in vitro activity of telithromycin against respiratory pathogens, isolated in outpatient clinics.
  
  
  METHODS
  Two hundred eighty strains isolated from patients with respiratory infections, were studied. The strains studied were S pneumoniae, penicillin sensitive (SPNS:57); intermediate (SPNI:35), resistant (SPNR:25); S pyogenes (SP:57); H influenzae (HIN 51); M catarrhalis (MC:25) and S aureus meticillin sensitive (SAUS:30). Minimal inhibitory concentration (MIC) by broth microdilution was studied for telitrhomycin and levofloxacin in all strains. Other antimicrobials studied, but not in all strains were erythromycin, clindamycin, trimetoprim sulphamethoxazole, oxacillin, amoxicillin-clavulanic acid and cefuroxime.
  
  
  RESULTS
  All strains were sensible to telithromycin at a concentration -4 microg/ml. MIC 90 and its range for SPNS was 0.03 microg/ml (-0.004-0.12), for SPNI was 0.03 microg/ml (-0.004-025), for SPNR was 0.06 microg/ml (-0.004-0.25), for HIN was 2 microg/ml (0.12-4), for SP was 0.5 microg/ml (-0.004-2), for MC was 0.5 microg/ml (0.06-2) and for SAU was 0.25 microg/ml (0.06-0.25).
  
  
  CONCLUSIONS
  All studied pathogens were sensible to telithromycin in vitro. This antimicrobial is an alternative for the treatment of community acquired respiratory infections.
authors.affiliation: Programa de Microbiología y Micología, Facultad de Medicina, Universidad de Chile, Independencia 1027, Clasificador 7, Independencia, Santiago, Chile. mtulloa@med.uchile.cl
authors.forename: María T
authors.initials: MT
authors.lastname: Ulloa F
authors.forename: Rossanna
authors.initials: R
authors.lastname: Camponovo C
authors.forename: Alejandra
authors.initials: A
authors.lastname: Fernández V
authors.forename: Patricia
authors.initials: P
authors.lastname: García C
authors.forename: Valeria
authors.initials: V
authors.lastname: Prado J
authors.forename: Patricia
authors.initials: P
authors.lastname: González A
authors.forename: Pamela
authors.initials: P
authors.lastname: Rojas S
authors.forename: Jaime
authors.initials: J
authors.lastname: Inostroza S
authors.forename: Mónica
authors.initials: M
authors.lastname: Lafourcade R
authors.forename: Liliana
authors.initials: L
authors.lastname: Aguilera A
authors.forename: Lorena
authors.initials: L
authors.lastname: Porte T
authors.forename: Carolina
authors.initials: C
authors.lastname: Cruz P
authors.forename: Alejandro
authors.initials: A
authors.lastname: Joyas M
authors.forename: Berta
authors.initials: B
authors.lastname: Alcaide L
authors.forename: María E
authors.initials: ME
authors.lastname: Pinto C
authors.forename: María S
authors.initials: MS
authors.lastname: Giglio M
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000188:drug therapy; D024881:Drug Resistance, Bacterial; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D048628:Ketolides / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects; D013290:Streptococcal Infections / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; C106791:telithromycin